Newsroom | 42585 results

WASHINGTON--(BUSINESS WIRE)--KeifeRx, a privately held biotechnology company developing disease-modifying therapies for neurodegenerative disorders, today announced that it has entered into a research collaboration and option agreement with Amneal Pharmaceuticals to support the pre-IND development of KFRX06, KeifeRx’s preclinical candidate designed to inhibit leucine-rich repeat kinase 2 (LRRK2), a gene strongly implicated in Parkinson’s disease biology. Under the agreement, KeifeRx will conduc...

JUPITER, Fla.--(BUSINESS WIRE)--Jupiter Medical Center (JMC) and Hospital for Special Surgery (HSS) are teaming up to expand access to the highest quality musculoskeletal care in South Florida. The alliance brings together Jupiter Medical Center, the region’s leading independent medical center, and HSS, ranked No. 1 in orthopedics by U.S. News & World Report for 16 straight years. Together, they will offer patients comprehensive orthopedic care—from diagnosis and surgery to rehabilitation—d...

LOS ANGELES--(BUSINESS WIRE)--Automated Industrial Robotics Inc. (“AIR” or the “Company”) today announced the acquisition of KAON Automation (“KAON”), an Ireland-based industrial automation company that delivers advanced automation solutions for leading manufacturing companies globally. In addition to strengthening AIR’s existing presence in Ireland, the transaction expands the Company’s presence in the medical and life sciences end markets and enhances its capabilities across precision assembl...

BRISBANE, Calif.--(BUSINESS WIRE)--Corporate presentation at 7:30 AM PST on January 15 in room Elizabethan A at the Westin St. Frances hotel, San Francisco...

BOSTON--(BUSINESS WIRE)--Elucid today announced that, effective January 1, 2026, its Plaque-IQ™ coronary plaque analysis has received a new Category I Current Procedural Terminology (CPT®) designation, alongside increasingly widespread coverage and reimbursement from both public and private payors. Together, these developments underscore the clinical value of coronary plaque analysis and establish favorable conditions for broader adoption of the technology. Quantitative coronary plaque analysis...

PROVO, Utah--(BUSINESS WIRE)--Nu Skin Enterprises Inc. (NYSE: NUS) today announced president and CEO Ryan Napierski will participate in a moderated fireside chat to discuss company strategy and the state of the business on Monday, Jan. 12. The discussion will include the company’s plans in 2026 for launching its Prysm iO intelligent wellness device and future opportunities in emerging markets, including India. The company's fireside chat will be webcast live beginning at 1:30 p.m. ET. Those wis...

BOSTON--(BUSINESS WIRE)--Aurora Therapeutics today announced its official launch to transform personalized gene editing from a one-patient breakthrough into a scalable model capable of bringing therapies to millions of patients with rare diseases. The company launches with a $16 million seed financing from Menlo Ventures to create the first platform for treating rare genetic mutations that have historically been impossible to address at scale. Aurora was founded by Jennifer Doudna, Ph.D., CRISP...

マサチューセッツ州ケンブリッジ--(BUSINESS WIRE)--（ビジネスワイヤ） -- ライフサイエンス分野の取引におけるAIネイティブ型デューデリジェンスの先駆者であるプルデンティア・サイエンシズは本日、シリーズAラウンドで2000万ドルの資金調達を完了したことを発表しました。本ラウンドはマッケソン・ベンチャーズが主導し、シグナルファイアが参加しました。既存投資家にはイアソ・ベンチャーズ、ヴァーチュー、GVが含まれます。これにより、2024年の700万ドルのシードラウンドに続き、同社の総資金調達額は2700万ドルに達しました。 プルデンティア・サイエンシズは、製薬企業、バイオテック企業、金融機関が画期的な医薬品を前例のない速度と厳密さで評価できるAIネイティブプラットフォームを提供します。複雑な臨床データを実用的な知見に統合することで、プルデンティアは案件処理を加速し、事業開発、投資、デューデリジェンスチームによる買収、ライセンス供与、投資判断に戦略的優位性を提供します。 同社の人間介在型アプローチは、買い手、売り手、仲介業者間のシームレスな連携を実現します。これにより、業界...

马萨诸塞州剑桥--(BUSINESS WIRE)--(美国商业资讯)-- 生命科学交易领域AI原生尽职调查的先驱Prudentia Sciences今日宣布完成2000万美元A轮融资。本轮融资由McKesson Ventures领投，SignalFire参投。现有投资者包括Iaso Ventures、Virtue和GV。继2024年完成700万美元种子轮融资后，该公司的融资总额已达2700万美元。 Prudentia Sciences提供AI原生平台，助力制药公司、生物技术公司和金融机构以前所未有的速度和严谨度评估突破性药物。公司将复杂的临床信号转化为可执行的洞察，从而加快交易流程，并为业务拓展、投资和尽职调查团队的收购、许可或投资决策提供战略支持。 公司的“人机回圈”模式能够协调买方、卖方和中介机构之间的无缝合作，以确保为行业最关键的投资决策提供安全合规的基础设施。 McKesson Ventures总裁Dave Schulte表示：“Prudentia正在革新生命科学机构利用数据评估资产和主动管理风险的方式。他们的AI原生平台通过实时洞察、无缝集成和智能自动化，加速科学尽职调查，将...

麻薩諸塞州，劍橋--(BUSINESS WIRE)--(美國商業資訊)-- 人工智慧原生生命科學領域交易盡職調查先驅Prudentia Sciences今天宣布獲得一筆2000萬美元的A輪融資。這一輪融資由McKesson Ventures領投，SignalFire也參與其中。其他投資者尚有Iaso Ventures、Virtue和GV。這使該公司的總資金達到2700萬美元；該公司的上一輪融資是在2024年完成的700萬美元種子輪融資。 Prudentia Sciences提供人工智慧原生平台協助製藥公司、生技公司和金融機構以前所未見的速度與嚴謹度評估突破性藥物的成效。Prudentia將複雜的臨床訊號綜合為可執行的見解，提高交易處理速度，並提出戰略支援輔助業務開發、投資和盡職調查團隊做出收購、許可或投資決策。 該公司採用人機迴圈模式，協調買家、賣家和仲介機構，確保各方無縫合作，為這個產業的重大投資決策提供安全合規的基礎設施。 「Prudentia正在現代化生命科學機構運用資料評估資產的方式，並積極管理風險。」McKesson Ventures總裁Dave Schulte說，「他們的人...